Advances in the Therapy of Advanced Ovarian Cancer-Special Emphasis on the PD1/PDL1 Pathway
Advances in the Therapy of Advanced Ovarian Cancer-Special Emphasis on the PD1/PDL1 Pathway
Authored By Kulvinder Kochar Kaur, Ovarian Cancer gets diagnosed in advanced stage in 75% of patient and
thus remains one of the most lethal gynecological malignancies. Despite
80% patients being responsive to platinum based chemotherapies to start
with most relapse finally. Hence need of the hour is to find more
effective immunotherapy’s to be added to these CRT. Programmed cell
death1 (PD1) -PDL1 is an important immune pathway which is discussed in
detail along with role of nivelumab (a monoclonal antibody against PD1)
and addition of other immunotherapy’s like bevacizumab, Olafarib (A PARP
(polyadenosine diphosphate (ADP)-ribose- inhibitor), C edinarib (a
VEGF123 inhibitor) etc to increase five year survival. Reasons of why
success not obtained as expected is further sought through Effect of
IFNγ on PDL1 pathway and different NK cellular phenotypes is further
analyzed besides role of NACT (neoadjunctive chemotherapy) on induction
of immune response.
Comments
Post a Comment